HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion

Autor: Audrey-Anne Lamoureux, Michael Fisher, Lauriane Lemelle, Elke Pfaff, Christof Kramm, Bram De Wilde, Bernarda Kazanowska, Caroline Hutter, Stefan M Pfister, Dominik Sturm, David Jones, Daniel Orbach, Gaëlle Pierron, Scott Raskin, Alexander Drilon, Eli Diamond, Guilherme Harada, Michal Zapotocky, Benjamin Ellezam, Alexander G Weil, Dominic Venne, Marc Barritault, Pierre Leblond, Hallie Coltin, Rawan Hammad, Uri Tabori, Cynthia Hawkins, Jordan R Hansford, Deborah Meyran, Craig Erker, Kathryn McFadden, Mariko Sato, Nicholas G Gottardo, Hetal Dholaria, Dorte Schou Nørøxe, Hiroaki Goto, David S Ziegler, Frank Y Lin, Donald Williams Parsons, Holly Lindsay, Tai-Tong Wong, Yen-Lin Liu, Kuo-Sheng Wu, Andrea Flynn Franson, Eugene Hwang, Ana Aguilar-Bonilla, Sylvia Cheng, Chantel Cacciotti, Maura Massimino, Elisabetta Schiavello, Paul Wood, Lindsey M Hoffman, Andréa Cappellano, Alvaro Lassaletta, An Van Damme, Anna Llort, Nicolas U Gerber, Mariella Spalato Ceruso, Anne E Bendel, Maggie Skrypek, Dima Hamideh, Naureen Mushtaq, Andrew Walter, Nada Jabado, Aysha Alsahlawi, Jean-Pierre Farmer, Christina Coleman Abadi, Sabine Mueller, Claire Mazewski, Dolly Aguilera, Nathan Robison, Katrina O’Halloran, Samuel Abbou, Pablo Berlanga, Birgit Geoerger, Ingrid Øra, Christopher L Moertel, Evangelia D Razis, Anastasia Vernadou, François Doz, Theodore W Laetsch, Sébastien Perreault

Publikováno v: Neuro-Oncology. 24:i61-i62

BACKGROUND: TRK fusions are detected in less than 3% of CNS tumors. Given their rarity, there are limited data on the clinical course of these patients. METHODS: We contacted 166 oncology centers worldwide to retrieve data on patients with TRK fusion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::70f58214dd53291eeabc1636fa6629a8
https://doi.org/10.1093/neuonc/noac079.226